Skip to main content
Livermore
Livermore
ZHEN

Dauntless Investment Group, LLC

SEC CIK
0002044285
Latest filing
Aug 13, 2026

The latest 13F from Dauntless Investment Group, LLC covers Q2 2026 (filed Aug 13, 2026): 64 long positions worth $57.7M. The top 10 holdings make up 63.6% of the portfolio, and the largest is AEON Biopharma, Inc. (AEON) at 15.6%. Livermore has 7 filings on Form 13F from this institution, going back to Q4 2024.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
23
Est. +$11.0M
Added
17
Est. +$26.9M
Reduced
18
Est. −$11.7M
Sold out
20
Est. −$3.70M

Top 5 holdings

Share of this quarter's portfolio value

  1. AEONAEON Biopharma, Inc.
    15.6%$8.98MHistory
  2. FEMYFemasys Inc
    13.5%$7.81MHistory
  3. KZIAKazia Therapeutics Ltd
    8.6%$4.99MHistory
  4. VLOValero Energy Corp
    4.8%$2.77MHistory
  5. JOEST JOE Co
    3.9%$2.27MHistory

Share of portfolio

Top 5 holdings and the other 59 positions, by share of portfolio value

  1. AEON15.6%
  2. FEMY13.5%
  3. KZIA8.6%
  4. VLO4.8%
  5. JOE3.9%
  6. Other 59 positions53.5%

Biggest buys

New and added positions, by estimated amount bought

  1. AEONAEON Biopharma, Inc.
    +$7.17MAddedHistory
  2. FEMYFemasys Inc
    +$6.55MAddedConverted for a 1-for-20 splitHistory
  3. KZIAKazia Therapeutics Ltd
    +$3.86MAddedHistory
  4. VLOValero Energy Corp
    +$2.77MNewHistory
  5. ADAGAdagene Inc.
    +$2.11MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AEONAEON Biopharma, Inc.
    +8.58 pp7.0% → 15.6%History
  2. KZIAKazia Therapeutics Ltd
    +6.98 pp1.7% → 8.6%History
  3. FEMYFemasys Inc
    +6.41 pp7.1% → 13.5%History
  4. VLOValero Energy Corp
    +4.80 pp0.0% → 4.8%History
  5. ADAGAdagene Inc.
    +3.53 pp0.4% → 3.9%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. INVAInnoviva, Inc.
    −$2.74MReducedHistory
  2. STLNStarling Oncology, Inc.
    −$1.62MReducedHistory
  3. LINCLincoln Educational Services Corp
    −$1.42MReducedHistory
  4. TLSATiziana Life Sciences Ltd
    −$1.28MReducedHistory
  5. CALMCal-Maine Foods Inc
    −$938.2KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. INVAInnoviva, Inc.
    −7.95 pp8.0% → 0.1%History
  2. TLSATiziana Life Sciences Ltd
    −4.54 pp7.1% → 2.6%History
  3. LINCLincoln Educational Services Corp
    −4.11 pp6.8% → 2.7%History
  4. CALMCal-Maine Foods Inc
    −2.80 pp3.2% → 0.4%History
  5. PPCPilgrims Pride Corp
    −2.66 pp3.3% → 0.7%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$57.7M
+$22.1M (+62.1%) vs. prior quarter
Positions
64
+3 vs. prior quarter
Top 10 concentration
63.6%
Top 10 as share of value
Turnover
33.1%
Q2 2026, one quarter
Average holding period
3.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $57.7M (Q2 2026)

Q4 2024: $23.7MQ1 2025: $27.1MQ2 2025: $21.3MQ3 2025: $38.1MQ4 2025: $27.2MQ1 2026: $35.6MQ2 2026: $57.7M
Q4 2024Q2 2026
13F filings of Dauntless Investment Group, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202664$57.7MAEONFEMYKZIAvs. Q1 2026SEC
Q1 2026May 14, 202661$35.6MINVAFEMYTLSAvs. Q4 2025SEC
Q4 2025Feb 17, 202653$27.2MJOEAGROLINCvs. Q3 2025SEC
Q3 2025Nov 14, 202542$38.1MTLSAOKYOAEMvs. Q2 2025SEC
Q2 2025Aug 14, 202561$21.3MTLSAOKYOJOEvs. Q1 2025SEC
Q1 2025May 7, 202546$27.1MOKYOFEMYTLSAvs. Q4 2024SEC
Q4 2024Feb 14, 202550$23.7MLINCNAKAGRO–SEC

13D and 13G filings

Companies where Dauntless Investment Group, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

3 companies, largest stake first.

Companies where Dauntless Investment Group, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
FEMYFemasys Inc13G/A9.90%4.40M shares+4.50 ppfrom 5.40%Feb 26, 20252 filingsNov 14, 2025SEC
AEONAEON Biopharma, Inc.13G9.70%108.2K sharesNewMar 3, 20251 filingMar 3, 2025SEC
AZTRAzitra, Inc.13G9.60%5.80M sharesNewJun 25, 20261 filingJun 25, 2026SEC

Latest filings

12 filings on file made by Dauntless Investment Group, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Dauntless Investment Group, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
AZTRAzitra, Inc.Jun 25, 20262:56 PM ET13G9.60%5.80M sharesNewJun 24, 2026SEC
OKYOOKYO Pharma LtdFeb 12, 20264:19 PM ET13G/A1.20%471.5K shares−5.10 ppfrom 6.30%Below 5%Dec 31, 2025SEC
KZIAKazia Therapeutics LtdFeb 12, 20264:15 PM ET13G/A0.00%1 shares−9.90 ppfrom 9.90%Below 5%Dec 31, 2025SEC
OKYOOKYO Pharma LtdNov 14, 202512:50 PM ET13G/A6.30%2.42M shares−1.00 ppfrom 7.30%Sep 30, 2025SEC
KZIAKazia Therapeutics LtdNov 14, 202512:48 PM ET13G/A9.90%176.8K shares+1.50 ppfrom 8.40%Sep 30, 2025SEC
FEMYFemasys IncNov 14, 202512:46 PM ET13G/A9.90%4.40M shares+4.50 ppfrom 5.40%Sep 30, 2025SEC
OKYOOKYO Pharma LtdAug 5, 20253:22 PM ET13G/A7.30%2.74M shares+1.40 ppfrom 5.90%Jun 30, 2025SEC
KZIAKazia Therapeutics LtdAug 5, 20253:19 PM ET13G/A8.40%115.8K shares+2.50 ppfrom 5.90%Jun 30, 2025SEC
KZIAKazia Therapeutics LtdJun 13, 20253:12 PM ET13G5.90%80.6K sharesNewJun 11, 2025SEC
OKYOOKYO Pharma LtdMar 18, 20252:35 PM ET13G5.90%2.00M sharesNewMar 12, 2025SEC
AEONAEON Biopharma, Inc.Mar 3, 20251:51 PM ET13G9.70%108.2K sharesNewFeb 26, 2025SEC
FEMYFemasys IncFeb 26, 20251:46 PM ET13G5.40%1.43M sharesNewFeb 18, 2025SEC